<DOC>
	<DOCNO>NCT00313222</DOCNO>
	<brief_summary>The present trial investigates possible use oral bosentan , currently approve treatment symptom pulmonary arterial hypertension ( PAH ) , patient suffer inoperable chronic thromboembolic pulmonary hypertension ( CTEPH ) ( ) peripheral localization thrombotic material ( ii ) persistent recurrent pulmonary hypertension pulmonary endarterectomy .</brief_summary>
	<brief_title>Bosentan Effects Inoperable Forms Chronic Thromboembolic Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Bosentan</mesh_term>
	<criteria>Symptomatic pulmonary hypertension modify NYHA functional class II IV due CTEPH demonstrate ventilation/perfusion lung scan pulmonary angiography . CTEPH judge inoperable peripheral localization thrombotic material persistent recurrent pulmonary hypertension pulmonary endarterectomy ( PEA ) evidence recurrent thromboembolism amenable repeat surgery . 6minute walk test ( 6MWT ) distance &lt; 450 m. Hemodynamic evaluation showing : Mean pulmonary arterial pressure ( mPAP ) &gt; = 25 mmHg ; Pulmonary capillary wedge pressure ( PCWP ) &lt; 15 mmHg ; Pulmonary vascular resistance ( PVR ) rest &gt; = 300 dyn×sec/cm5 For patient underwent PEA , hemodynamic evaluation must perform 6 month PEA . For patient , hemodynamic evaluation must perform 3 month immediately precede inclusion . Men woman &gt; = 18 = &lt; 80 year age ( Women childbearing potential must negative pretreatment pregnancy test use reliable method contraception ) . Anticoagulants efficacious dose least 3 month prior randomization . Signed informed consent prior initiation studymandated procedure . Other form pulmonary hypertension include pulmonary hypertension relate sickle cell disease . Obstructive lung disease : FEV1/FVC &lt; 0.5 bronchodilator . Severe restrictive lung disease : Total Lung Capacity &lt; 60 % predict value . Acute chronic impairment ( dyspnea ) , limit ability comply study requirement ( particular 6MWT ) , e.g. , angina pectoris , intermittent claudication . Symptomatic pulmonary embolism within 6 month prior randomization . Pulmonary endarterectomy within 6 month prior randomization . Psychotic , addictive disorder limit ability provide inform consent comply study requirement . Illness life expectancy le 6 month . Moderate severe hepatic impairment , i.e. , ChildPugh Class B C. AST and/or ALT &gt; 3 time upper limit normal ranges.· Hemoglobin concentration &lt; 75 % low limit normal range . Pregnancy breastfeed . Systolic blood pressure ( BP ) &lt; 85 mmHg . Treatment plan treatment another investigational drug and/or pulmonary angioplasty within 3 month prior randomization . Treatment endothelin receptor antagonist , phosphodiesterase inhibitor , Larginine prostanoids ( exclude acute administration catheterization procedure test vascular reactivity ) within 3 month prior randomization . Treatment pulmonary hypertension within 1 month prior randomization , exclude calcium channel blocker present least 1 month randomization . Treatment calcineurininhibitors ( e.g. , cyclosporine A tacrolimus ) , sirolimus , fluconazole , glibenclamide ( glyburide ) within 1 week prior randomization . Known hypersensitivity bosentan excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>CTEPH</keyword>
	<keyword>bosentan</keyword>
</DOC>